6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-2H,3H,4H-pyrido[3,2-b][1,4]oxazin-3-one

• ChemBase编号: 4812
• 分子式: C22H23FN6O5
• 平均质量: 470.4536232
• 单一同位素质量: 470.17139609
• SMILES: N1c2nc(Nc3nc(ncc3F)Nc3cc(c(c(c3)OC)OC)OC)ccc2OC(C1=O)(C)C
• Canonical SMILES: COc1cc(Nc2ncc(c(n2)Nc2ccc3c(n2)NC(=O)C(O3)(C)C)F)cc(c1OC)OC
• InChI: InChI=1S/C22H23FN6O5/c1-22(2)20(30)28-19-13(34-22)6-7-16(27-19)26-18-12(23)10-24-21(29-18)25-11-8-14(31-3)17(33-5)15(9-11)32-4/h6-10H,1-5H3,(H3,24,25,26,27,28,29,30)
• InChIKey: NHHQJBCNYHBUSI-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-2H,3H,4H-pyrido[3,2-b][1,4]oxazin-3-one
• IUPAC传统名: 6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one
• 别名: 6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one; 6-[[5-Fluoro-2-[(3,4,5-trimethoxyphenylamino]pyrimidin-4-ylamino]-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one; 6-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,2-dimethyl-2H-pyrido[3,2-b]-1,4-oxazin-3(4H)-one; R406(free base)

登记号

• CAS号: 841290-80-0
• PubChem SID: 160968244; 99443630
• PubChem CID: 11213558

理论计算性质

JChem

• Acid pKa: 10.57069
• 质子受体: 10
• 质子供体: 3
• LogD (pH = 5.5): 3.621819
• LogD (pH = 7.4): 3.626315
• Log P: 3.6266596
• 摩尔折射率: 122.0046 cm^3
• 极化性: 44.999313 Å^3
• 极化表面积: 128.75 Å^2
• 可自由旋转的化学键: 7
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 3.84
• LOG S: -4.21
• 溶解度: 2.91e-02 g/l

分子性质

安全信息

• 保存条件: -20°C

药理学性质

• 作用靶点: Syk

产品相关信息

• 成盐信息: Free Base

详细说明

DrugBank - DB07159

Drug information: experimental

Selleck Chemicals - S1533

Research Area

• Description: Cancer

Biological Activity

• Description: R406 is a potent spleen tyrosine kinase (Syk) inhibitor with EC50 and K_i of 56 nM and 30 nM, respectively.
• Targets: Syk; Syk
• IC50: 56 nM (EC50); 30 nM (K_i) ^[1]
• In Vitro: R406 is a potent inhibitor of immunoglobulin E (IgE)- and IgG-mediated activation of Fc receptor signaling. R406 inhibits the anti-IgE-induced production and release of LTC4 and cytokines and chemokines, including TNFα, IL-8, and GM-CSF. R406 inhibits phosphorylation of Syk substrate linker for activation of T cells in mast cells and B-cell linker protein/SLP65 in B cells. R406 binds to the ATP binding pocket of Syk and inhibits its kinase activity as an ATP-competitive inhibitor with K_i of 30 nM. R406 blocks Syk-dependent FcR-mediated activation of monocytes/macrophages and neutrophils and Bcr-mediated activation of B lymphocytes. ^[1] R406 significantly induces chronic lymphocytic leukemia (CLL) cell apoptosis in nurselike cells cocultures and blocks CCL3 and CCL4 secretion by CLL cells in response to B-cell antigen receptor (Bcr) triggering. ^[2] R406 is a potent inhibitor of platelet signaling and functions initiated by FcγRIIA cross-linking by specific antibodies or by sera from HIT patients. ^[3]
• In Vivo: R406 reduces cutaneous reverse passive Arthus reaction by approximately 86% at 5 mg/kg in prophylactic treated mice. R406 also shows efficacy in inhibiting paw inflammation in antibody-induced arthritis mouse models. ^[1] R406 does not adversely affect macrophage or neutrophil function in innate immune responses and has minimal functional immunotoxicity notwithstanding its lymphocytopenic effect. ^[4]
• Clinical Trials: R406’s prodrug, Fostamatinib, is completed in Phase I clinical trials in subjects with rheumatoid arthritis or renal impairment.
• Features: Lead drug candidate for rheumatoid arthritis

Protocol

• Protocol: Kinase Assay ^[1]
• In Vitro Fluorescence Polarization Kinase Assay: R406 is serially diluted in DMSO and then diluted to 1% DMSO in kinase buffer (20 mM HEPES, pH 7.4, 5 mM MgCl₂, 2 mM MnCl₂, 1 mM DTT, 0.1 mg/mL acetylated BGG). ATP and substrate in kinase buffer are added at room temperature, resulting in a final DMSO concentration on 0.2%. The kinase reactions are performed in a final volume of 20?mL containing 5?mM HS1 peptide substrate, 4?mM ATP and started by addition of 0.125 ng of Syk in kinase buffer. The reaction is allowed to proceed for 40 minutes at room temperature. The reaction is stopped by the addition of 20?mL of PTK quench mix containing EDTA/anti-phosphotyrosine antibody (1X final)/fluorescent phosphopeptide tracer (0.5X final) diluted in FP Dilution Buffer. The plate is incubated for 30 minutes in the dark at room temperature and then read on a Polarion fluorescence polarization plate reader. Data are converted to amount of phosphopeptide present using a calibration curve generated by competition with the phosphopeptide competitor provided in the Tyrosine Kinase Assay Kit. For IC50 determination, R406 is tested at eleven concentrations and curve-fitting is performed by non-linear regression analysis.
• Ki Determination: For K_i determination, duplicate 200-μL reactions are set up at eight different ATP concentrations from 200 μM (2-fold serial dilutions) in the presence of either DMSO or R406 at 125, 62.5, 31.25, 15.5, or 7.8 nM. At different time points, 20 μL of each reaction is removed and quenched to stop the reaction. For each concentration of R406, the rate of reaction at each concentration of ATP is determined and plotted against the ATP concentration to determine the apparent K_m and V_max (maximal rate). Finally the apparent K_m (or apparent K_m/V_max) is plotted against the inhibitor concentration to determine the K_i.
• Protocol: Animal Study ^[1]
• Animal Models: Arthritis is induced in C57BL/6 mice by intraperitoneal injection of 150 μL of pooled sera from adult K/BxN mice.
• Formulation: 35% TPGS, 60% PEG 400, and 5% propylene glycol
• Doses: 1 or 5 mg/kg
• Administration: Administered orally

References

• References: [1] Braselmann S, et al. J Pharmacol Exp Ther, 2006, 319(3), 998-1008.
• References: [2] Quiroga MP, et al. Blood, 2009, 114(5), 1029-1037.
• References: [3] Lhermusier T, et al. J Thromb Haemost, 2011, 9(10), 2067-2076.
• References: [4] Zhu Y, et al. Toxicol Appl Pharmacol, 2007, 221(3), 268-277.

Toronto Research Chemicals - F596600

Intermediate used for preparation of prodrugs of pyrimidine-2,4-diamines as anticancer agents.

参考文献

• Braselmann S, et al. J Pharmacol Exp Ther, 2006, 319(3), 998-1008.
• Quiroga MP, et al. Blood, 2009, 114(5), 1029-1037.
• Lhermusier T, et al. J Thromb Haemost, 2011, 9(10), 2067-2076.
• Zhu Y, et al. Toxicol Appl Pharmacol, 2007, 221(3), 268-277.
• Atwell, S., et al.: J. Biol. Chem., 279, 55827 (2004)
• Braselmann, S., et al.: J. Pharmacol. Exp. Ther., 319, 998 (2004)
• Hirabayashi, A., et al.: Bioorg. Med. Chem., 16, 7347 (2004)